ResearchThe Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trialsMichael Shaw1 , John Dent2 , Timothy Beebe3 , Ola Junghard4 , Ingela Wiklund4 , Tore Lind4 and Folke Johnsson5  1Park Nicollet Clinic and University of Minnesota Medical School, Minneapolis, MN 55416-2699, USA 2Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia 3Mayo Clinic College of Medicine, Rochester, MN 55905, USA 4AstraZeneca R&D, SE-431 83 Mölndal, Sweden 5University of Lund, SE-221 00 Lund, Sweden author email corresponding author email
Health and Quality of Life Outcomes 2008,
6:31doi:10.1186/1477-7525-6-31 Abstract
Background
Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian.
Methods
Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor.
Results
The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89.
Conclusion
The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity. |